Recent Company News

• 03:05 PM ET Apr 17, 2025
  

  StreetAccount Activist Summary: Week of 14-Apr

• 02:34 AM ET Apr 15, 2025
  

  Biotest holder Westbourne River Partners expresses concerns over Grifols delisting offer in letter to Biotest's board (€30.00, 0.00)

• 12:33 PM ET Apr 07, 2025
  

  StreetAccount M&A Summary: Week of 31-Mar

• 02:50 AM ET Mar 31, 2025
  

  Biotest concludes delisting agreement with Grifols; Grifols Biotest Holdings GmbH to make unconditional public delisting acquisition offer for Biotest AG for €43.00/share in cash (€29.30, 0.00)

• 01:09 AM ET Mar 31, 2025
  

  Biotest reports FY net income €26.4M vs year-ago €127.0M; guides 2025 Operating result (EBIT) in the range of (€55M) to (€75M) (€29.30, 0.00)

• 03:08 AM ET Mar 06, 2025
  

  Biotest CFO Martin Möller to step down as planned at the end of his contract on 15-Mar; aims to fill CFO position in the near future (€29.20, 0.00)

• 12:26 PM ET Feb 26, 2025
  

  Biotest reports preliminary FY24 EBIT €94.5M vs year-ago €143.5M (€28.60, 0.00)

• 03:02 AM ET Jan 09, 2025
  

  Biologics License Application for Fibrinogen submitted to the FDA (€27.00, 0.00)

• 04:21 AM ET Nov 14, 2024
  

  Biotest reports Q3 net income (€9.3M) vs year-ago €86.6M (€26.90, +0.10)

• 03:01 AM ET Nov 14, 2024
  

  Biotest corrects FY24 forecast for revenue, cash flow and ROCE; EBIT guidance unchanged (€26.80, 0.00)